Reinventing miRNA cancer therapy through immunomodulation and AI

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• MicroRNA (miRNA) therapeutics offer rational strategies for cancer treatment by regulating gene expression.
• Clinical translation of miRNA-based therapies is hindered by molecular instability, off-target effects, and delivery challenges.

Purpose of the Study:

• To review the therapeutic potential of miRNAs in oncology.
• To delineate current challenges in miRNA clinical translation.
• To highlight emerging frontiers for advancing miRNA-based cancer therapies.

Main Methods:

• Systematic review of current literature on miRNA therapeutics in oncology.
• Analysis of challenges in miRNA stability, delivery, and biological complexity.
• Exploration of novel therapeutic strategies and computational approaches.

Main Results:

• miRNAs hold significant potential as gene regulators in cancer.
• Key challenges include in vivo target validation, long-term safety, and interpretability of computational models.
• Integration with immunotherapy and AI application are pivotal for future development.

Conclusions:

• Advancing miRNA therapy requires addressing molecular and delivery hurdles.
• Combining miRNA therapeutics with immunotherapy and leveraging AI are crucial next steps.
• A convergent approach integrating advanced delivery, precision medicine, and collaboration is essential for clinical success.